Next Phase Newsletter

A Canada-based venture capital firm makes investments with an average size of $5 million with reserves left for follow-on rounds. The firm seeks to make 4-5 new investments per year, and typically co-invests in seed, venture and series A investments at $50,000 – $1M per company. The firm has partnerships with medical software/device, fintech and ICT funds in which the firm will pass on deal flow. The firm has particular preference to companies located in North America, though is open to Australia and Western Europe depending on the opportunity. The firm does not request distribution rights for international investments.

The firm is interested in early-stage wearable technology and software-enabled technology, particularly ones that can improve hospital operations. The firm does not have a preference for any specific indication areas. The firm does not have revenue requirements for wearable technology and is not particularly interested in products that require regulatory pathways. The firm is interested in companies that are in the development or clinical-stage but will only invest in healthcare IT companies if it is already established with positive cash flow. Outside of software and wearable technology, the firm will look at medical devices to evaluate and connect to partnered funds.

The firm values sweat equity but the firm will not make any investments into a company unless the founding team has invested their own funds into the company’s success. The firm takes a board seat when making any new investments and looks for strong, experienced management teams. The first question the firm will ask any new opportunity is whether or not they have experience in marketing, sales, startups, or the industry they are entering. The firm can provide strategic management if necessary.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital company based in Texas makes equity investments into early stage companies generally in Angel and Seed rounds. For early stage opportunities, the firm typically invests up to $.5 million dollars but is able to invest more or less depending on the opportunity. Additionally the firm partners with a large number of investors in China who are interested in later stage opportunities where they can invest $15M-$20M. The firm is looking for companies located in the United States and generally makes 2-3 new investments per year.

The firm is looking for companies in sectors of Healthcare IT, Medical Devices, Telemedicine, Mobile Health and Bioinformatics. The firm looks for companies that have at least a prototype of their product and has made investment into several companies that have pre-market approval. The firm is agnostic in terms of subsector and indication and is very open to review any companies in their sectors of interest. More recently the firm has also gained interest into companies that are interested in accessing China market for business and investment opportunities.

The firm is looking for companies with experienced management teams and generally looks to take a board seat following investment. The firm is also open to syndication with other investors in certain cases.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The venture arm of a medtech corporation makes equity investments in life science companies, typically in venture rounds. The firm invests at a wide range of product development phases, from preclinical development (up to 18 months away from the first in-human clinical trials) to products that have received regulatory approval, but typically does not invest in products that are on the market. The fund is open to considering investments globally.

The firm invests in areas that are strategically important to its parent corporation, primarily the medical device sector and the diagnostics sector. Within diagnostics, the fund is interested in molecular diagnostics, point of care diagnostics, and immunoassay and clinical chemistry systems. The firm’s areas of interest include cardiovascular diseases, diabetes and ophthalmology. The fund also invests in infant nutrition and nutraceuticals.

The firm invests only in privately-held companies, but has no other fixed requirements for companies & management teams.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The investment arm of a large food and beverage conglomerate headquartered in Asia invests from a fund of about US$ 500 million. The firm invests in several sectors including healthcare. Typical equity investment ranges from US0.5-5 million in early stage businesses. The firm is open to either leading or following in a financing round. PIDC is currently looking for opportunities from Taiwan, North America, and Europe.

Within healthcare, the firm considers therapeutics, medical devices, and biotech R&D services. In therapeutics, the firm is interested in projects with preclinical or initial clinical validation. The firm takes an opportunistic approach when it comes to medical devices and R&D services. The firm is agnostic to disease areas. Historically, the firm has invested in a specialty pharmaceutical company, a robotic radiosurgery company, and a process R&D and API manufacturing service provider.

The firm is looking for experienced management teams with sector expertise. The firm may request board representation post-investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm founded in 2016 with offices in the USA and China generally invests $1-5M (USD) of equity capital and aims to make 3-5 investments per year, but this is not a fixed number. In general, the firm participates in seed and series A funding rounds. The firm looks at companies of all parts of the world and has a strong preference for companies that have market opportunities in Asian markets, particularly China. The firm’s China office will provide companies with the resources they need for successful market entry.

The firm looks at all sectors pertaining to healthcare, including biotech therapeutics, R&D services, diagnostics, medical devices, and digital health. While the firm’s focus is in early-stage companies, it takes a very opportunistic viewpoint. In therapeutics, the firm will look at products of all stages from pre-clinical to phase III, and is open to all indications. In terms of medical devices, the firm will consider both 510k and PMA devices. In addition, the firm will also consider products that are already on the market.

The firm is open to both public and private companies, and expects them to have an experienced management team with a strong exit strategy. The firm requires a board seat in all portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A privately funded investment firm based in Canada focuses on making direct investments in the following business sectors: medical technology, medical clinics, healthcare IT and healthcare real estate.  In medtech, the firm seeks to invest in seed stage companies.  The firm looks to partner and fund scientific founders to launch a new company and will primarily invest in the seed stage round. The firm typically allocates $100K-$200K, and will syndicate with other investors outside of their region (including Australia) to invest in larger rounds of $500K or more. The firm has physician, medical experience, particularly in the surgical field. The firm invests globally and is currently seeking new investment opportunities.

In the life sciences, the firm is currently seeking to invest in medical devices and healthcare IT. The firm is opportunistic in terms of the class of device and indications, and has particular interest in surgical devices and tools. The firm is additionally interested in digital health, especially those with a software component. The firm prefers to invest in the pre-prototype stage and with particular preference to very early-stage preclinical technology.

The firm is seeking pre-revenue companies. The firm is very hands-on after an investment, opening up and bringing their network to their portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

An asset management firm that was founded in 2014 and is headquartered in Shanghai, China, is focused on angel and early stage investments in several industry sectors including healthcare. Typical investments range from US$0.2-2 million. The firm is open to leading or following in a financing round. The firm is looking for opportunities from China and the US.

The firm is interested in medical device, diagnostic, consumer and mobile health products that address pain points and rigid demand in the market and have unique entry barrier. The firm prefers products that have a short regulatory pathway to market. The firm typically invests in companies in seed and angel stages.

The firm works with teams with strong technical expertise and high growth potential. The firm is interested in overseas companies with a China angle and can provide technical, management, and distribution resources. The firm may request a board seat on a case-by-case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com